1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The Ergot Alkaloids were the very first anti-migraine-specific therapy class to reach the market. The first pure ergot alkaloid was isolated in 1920, but only in 1925 was ergotamine used to successfully treat a case of severe and intractable migraine via subcutaneous injection (Rothlin, 1955; Stoll, 1965). Over the following decades, ergotamine’s use as a migraine treatment was investigated by various researchers and its potent vasoconstriction properties reinforced the belief that migraine had a vascular origin.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Ergot Alkaloids including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Ergot Alkaloids for the top two countries from 2012 to 2023.
- Sales information covered for the US and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Ergot Alkaloids performance
- Obtain sales forecast for Ergot Alkaloids from 2012-2023 in the top two countries (the US and Japan)

Table Of Contents

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 16
3.2 Symptoms 16
3.2.1 Premonitory Phase 17
3.2.2 Aura Phase 17
3.2.3 Headache Phase 18
3.2.4 Postdrome Phase 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Acute Migraine Treatment 22
4.1.2 Preventive Migraine Treatment 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Ergot Alkaloids 27
6.1 Overview 27
6.2 Efficacy 29
6.3 Safety 31
6.4 SWOT Analysis 32
6.5 Forecast 32
7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 37
7.3 Methodology 39
7.4 Forecasting Methodology 39
7.4.1 Diagnosed Migraine Patients 39
7.4.2 Percent Drug-treated Patients 39
7.4.3 General Pricing Assumptions 40
7.4.4 Individual Drug Assumptions 41
7.4.5 Generic Erosion 41
7.5 Physicians and Specialists Included in this Study 42
7.6 Survey of Prescribing Physicians 43
7.7 About the Authors 44
7.7.1 Author 44
7.7.2 Reviewer 44
7.7.3 Global Head of Healthcare 45
7.8 About GlobalData 46
7.9 Disclaimer 46

1.1 List of Tables

Table 1: Classification of Migraine Subtypes 13
Table 2: Diagnostic Criteria for Migraine with Aura 17
Table 3: Diagnostic Criteria for Migraine without Aura 18
Table 4: Treatment Guidelines for Migraine 20
Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013 21
Table 6: Product Profile - Ergot Alkaloids 28
Table 7: Ergot Alkaloids SWOT Analysis, 2013 32
Table 8: Global Sales Forecasts ($m) for Ergot Alkaloids, 2012-2023 33
Table 9: Physicians Surveyed, By Country 43

1.2 List of Figures

Figure 1: Migraine Treatment Algorithm in the 7MM 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Sumatriptan Market Research Report 2016

Global Sumatriptan Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Sumatriptan Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Sumatriptan industry, focusing on the main regions (North America, ...

2016 Eletriptan (CAS 177834-92-3) Global Market Report

2016 Eletriptan (CAS 177834-92-3) Global Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Eletriptan Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Eletriptan industry with a focus on the Chinese market. ...

2016 Global Ergotamine (CAS 113-15-5) Industry Market Report

2016 Global Ergotamine (CAS 113-15-5) Industry Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Ergotamine Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Ergotamine industry with a focus on the Chinese market. ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective and Therapy Market in the US - Forecast

  • December 2016
    249 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Anti-Infective and Therapy Market in the US

  • November 2016
    249 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Therapy Market in the US

  • October 2016
    248 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Related Market Segments :

Antimigraine
Therapy
Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.